Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial

Open access
Sharp, Andrew, Cornforth, Christine, Jackson, Richard, Harrold, Jane, Turner, Mark A, Kenny, Louise C, Baker, Philip N, Johnstone, Edward D, Khalil, Asma, von Dadelszen, Peter, Papageorghiou, Aris T, Alfirevic, Zarko, Agarwal, Umber, Willis, Elaine, Mammarella, Silvia, Masson, Geraldine, Aquilina, Joe, Greco, Elena, Higgins, Sally, Vinayagam, Dimuthu, Shaw, Louise, Stephens, Louise, Howe, David, Rand, Abby, Patni, Shalini, Mousa, Tommy, Rabab, Asma, Russell, Helen, Hannon, Therese, Fenn, Andrea, Kilby, Mark, Selman, Tara, David, Anna, Spencer, Rebecca, Cohen, Kelly, Breeze, Andrew, McKelvey, Alastair, Impey, Lawrence, Loannou, Christos, Stock, Sarah, Poon, Liona, Pasupathy, Dharmintra, Webster, Louise, Bugg, George · 2018 · The Lancet Child & Adolescent Health

Abstract

BACKGROUND: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which leads to vasodilatation of the uterine vessels and might improve fetal growth in utero. METHODS: We did this superiority, placebo-controlled randomised trial in 19 fetal medicine units in the UK. We used random computer allocation (1:1) to assign women with singleton pregnancies between 22 weeks and 0 days' gestation and 29 weeks and 6 days' gestation and severe early-onset fetal growth restriction to receive either sildenafil 25 mg three times daily or placebo until 32 weeks and 0 days' gestation or delivery. We stratified women by site and by their gestational age at randomisation (before week 26 and 0 days or at week 26 and 0 days or later). We defined fetal growth restriction as a combination of estimated fetal weight or abdominal circumference below tenth percentile and absent or reversed end-diastolic blood flow in the umbilical artery on Doppler velocimetry. The primary outcome was the time from randomisation to delivery, measured in days. This study is registered with BioMed Central, number ISRCTN 39133303. FINDINGS: Between Nov 21, 2014, and July 6, 2016, we recruited 135 women and randomly assigned 70 women to sildenafil and 65 women to placebo. We found no difference in the median randomisation to delivery interval between women assigned to sildenafil (17 days [IQR 7-24]) and women assigned to placebo (18 days [8-28]; p=0·23). Livebirths (relative risk [RR] 1·06, 95% CI 0·84 to 1·33; p=0·62), fetal deaths (0·89, 0·54 to 1·45; p=0·64), neonatal deaths (1·33, 0·54 to 3·28; p=0·53), and birthweight (-14 g,-100 to 126; p=0·81) did not differ between groups. No differences were found for any other secondary outcomes. Eight serious adverse events were reported during the course of the study (six in the placebo group and two in the sildenafil group); none of these were attributed to sildenafil. INTERPRETATION: Sildenafil did not prolong pregnancy or improve pregnancy outcomes in severe early-onset fetal growth restriction and therefore it should not be prescribed for this indication outside of research studies with explicit participants' consent. FUNDING: National Institute for Health Research and Medical Research Council.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-4642(17)30173-6

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 196

Metadata

Authors
Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., Baker, P. N., Johnstone, E. D., Khalil, A., von Dadelszen, P., Papageorghiou, A. T., Alfirevic, Z., Agarwal, U., Willis, E., Mammarella, S., Masson, G., Aquilina, J., Greco, E., Higgins, S., Vinayagam, D., Shaw, L., Stephens, L., Howe, D., Rand, A., Patni, S., Mousa, T., Rabab, A., Russell, H., Hannon, T., Fenn, A., Kilby, M., Selman, T., David, A., Spencer, R., Cohen, K., Breeze, A., McKelvey, A., Impey, L., Loannou, C., Stock, S., Poon, L., Pasupathy, D., Webster, L., & Bugg, G.
Venue
The Lancet Child & Adolescent Health
Publisher
Elsevier BV
Published
2018-02
Volume
2
Issue
2
Pages
93-102
ISSN
2352-4642 (ISSN-L)
OpenAlex
W2772417060
Cited by
196
References
4
FWCI
24.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. https://app.cochat.ai/papers/10.1016/s2352-4642(17)30173-6
The paper
Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., Baker, P. N., Johnstone, E. D., Khalil, A., von Dadelszen, P., Papageorghiou, A. T., Alfirevic, Z., Agarwal, U., Willis, E., Mammarella, S., Masson, G., Aquilina, J., Greco, E., Higgins, S., . . . Bugg, G. (2018). Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. The Lancet Child & Adolescent Health. https://doi.org/10.1016/s2352-4642(17)30173-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.